Answers are grounded in this paper and cite their sources.
Sulforhodmaine B lowers T in alveolar edema liquid. Given the problematic intratracheal delivery of surfactant therapy for ARDS, intravenous SRB might constitute an alternative therapeutic. In a lung injury model, we find that intravenously administered SRB crosses the injured alveolar-capillary barrier, reduces T specifically in injured lung regions, improves oxygenation, and reduces the degree of further lung injury. Intravenous SRB administration might help respiratory distress patients, including those with the novel coronavirus, avoid mechanical ventilation or, once ventilated, survive.
No takes yet. Share an insight, caveat, or question.
Wu et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: